Tirzepatide Therapy: A Step-by-Step Guide to How Treatment Works

Step 1: Clinical assessment — before the first pen

Tirzepatide is a prescription-only medicine, so the process begins with a clinical consultation, not a checkout basket. A prescriber reviews your health history, current medicines, BMI, and any relevant conditions before deciding whether tirzepatide is appropriate for you. At nume, that review is carried out by a GPhC-registered Independent Prescriber, personally, the same day you submit your consultation.

This stage also catches the contraindications worth knowing about. A history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or certain gastrointestinal conditions requires careful prescriber discussion. So does a history of pancreatitis. Women using oral contraceptives should know that tirzepatide may reduce pill absorption during the first four weeks of treatment and after each dose increase, so a non-oral method is recommended alongside it during those windows — NHS guidance is specific on this point.

For anyone transferring from another provider, evidence of current treatment and dose is part of the assessment. The consultation is where these details matter, and getting them right from the start shapes how smoothly therapy progresses. If you want to understand the broader treatment landscape before that point, our weight-loss treatment overview covers the options.

Step 2: Starting and titrating, the first few months

The 2.5 mg starting dose exists to settle your system, not to produce immediate weight loss. Its job is tolerability: giving your digestive system time to adapt to slower gastric emptying before the therapeutic doses begin. Most people move through the schedule in roughly 4-week steps, guided entirely by the prescriber based on how well each level is tolerated.

The progression runs 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, though not everyone reaches the highest strength, and that is not a failure. The prescriber's goal is the highest dose you can tolerate well, not the highest dose on the label. Early side effects are common and tend to be gastrointestinal: nausea, loose stools, indigestion, burping. They are most noticeable in the days after starting or after an increase, and they typically ease within one to two weeks as the body adjusts.

One practical point many people overlook early on: the pen lives in the fridge, between 2 and 8 °C, most people keep it in the fridge door next to everyday items, which helps build the habit. There is a limited window for room-temperature storage; the Patient Information Leaflet sets out the exact timeframe and it is the right document to follow, not a general online summary.

For a closer look at the full UK product profile, our tirzepatide overview covers the licensed details. If you have been wondering whether an oral form of tirzepatide exists, that page addresses the current evidence and what is in development.

Step 3: Ongoing therapy, what long-term management looks like

Once on a stable maintenance dose, the focus shifts from adjustment to consistency. Weekly injections continue, appetite tends to be substantially reduced, and the clinical work becomes about supporting the lifestyle changes that make the weight loss sustainable: adequate protein, hydration, fibre, and regular activity.

Evidence from the SURMOUNT-1 trial, published in the New England Journal of Medicine, found average body-weight reductions of around 20–21% at the 15 mg dose over 72 weeks, in participants who combined treatment with reduced-calorie eating and increased activity. Those figures reflect thousands of adults in a structured research setting, real-world results vary, and a prescriber can give you a realistic picture for your situation.

Repeat prescriptions are not automatic. Each time a patient requests a repeat at nume, the prescriber reviews the case afresh, which is consistent with how responsible long-term prescribing of any POM should work. If you are curious about how costs are structured across a course of treatment, our guide to Mounjaro pricing in the UK breaks down what legitimate private prescriptions typically include. NICE's published appraisal of tirzepatide, TA1026, sets out the evidence base the NHS uses to evaluate this treatment and is worth reading if you want the full clinical picture.

Step 4: Deciding which route suits you

Tirzepatide reaches patients through two routes in the UK: NHS and private. NHS access through NICE TA1026 is phased and currently restricted to patients with a BMI of 40 or above and four or more specific weight-related conditions, with Cohort 2 (BMI 35–39.9 with four or more conditions) activated in June 2026. Ethnic-background thresholds are 2.5 kg/m² lower throughout. Waiting lists and local commissioning add further variation. Patients who are approaching the ceiling of the titration schedule may also find it useful to read about tirzepatide at the 30-unit mark, including what that means in practice for dosing and pen management.

Private prescribing through a regulated online pharmacy like nume removes the waiting list and the referral requirement, subject to clinical suitability. The trade-off is cost: private treatment is paid for directly, and the price includes the clinical assessment, prescription, and dispensing. It is not the right route for everyone, but for people who do not meet current NHS criteria, or who do not want to wait, it is a legitimate, regulated option. Our page on tirzepatide l goes into further detail on the formulation options available through private routes.

If you are weighing up whether tirzepatide or semaglutide is the better fit, our Mounjaro or tirzepatide comparison works through the clinical distinctions. You can also review what a consultation with our team involves on the treatments page before taking the next step.